Ge Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GE HLTHCARE, and when can generic versions of GE HLTHCARE drugs launch?
GE HLTHCARE has two approved drugs.
There are six US patents protecting GE HLTHCARE drugs.
There are ninety-nine patent family members on GE HLTHCARE drugs in twenty-two countries and four supplementary protection certificates in four countries.
Summary for Ge Hlthcare
| International Patents: | 99 |
| US Patents: | 6 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Ge Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | 7,344,702 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | 9,603,951 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Ge Hlthcare | FLYRCADO | flurpiridaz f-18 | SOLUTION;INTRAVENOUS | 215168-001 | Sep 27, 2024 | RX | Yes | Yes | 9,161,997 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ge Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Hlthcare Inc | DATSCAN | ioflupane i-123 | SOLUTION;INTRAVENOUS | 022454-001 | Jan 14, 2011 | 5,310,912 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ge Hlthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2018076328 | ⤷ Subscribe |
| Singapore | 10201500929X | ⤷ Subscribe |
| Japan | 6685269 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ge Hlthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0703791 | C300123 | Netherlands | ⤷ Subscribe | PRODUCT NAME: IOFLUPANE (123I); NAT. REGISTRATION NO/DATE: EU/1/00/135/001 20000727; FIRST REGISTRATION: EU/1/00/135/001 20000727 |
| 0703791 | 03C0021 | France | ⤷ Subscribe | PRODUCT NAME: IOFLUPANE (123 I); REGISTRATION NO/DATE: EU/1/00/135/001 20000727 |
| 0703791 | SPC/GB03/010 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: IOFLUPANE (123I) OR (123I)-2-BETA-CARBOMETHOXY-3-BETA-(4-IODOPHENYL)-8-(3-FLUOROPROPYL)-NORTROPANE; REGISTERED: UK EU/1/00/135/001 20000802 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
